Livagen Research Overview (also known as Khavinson Liver Peptide, KEDA (Lys-Glu-Asp-Ala), Liver Bioregulator Peptide)
A tetrapeptide bioregulator (Lys-Glu-Asp-Ala / KEDA) from the Khavinson family, targeting liver, lymphocytes, and GI/immune systems. Acts via chromatin decondensation in aged nuclei, restoring gene expression and protein synthesis in hepatocytes and lymphocytes, and inhibits enkephalin-degrading enzymes (IC₅₀ ≈ 20 μM) to prolong endogenous opioid signaling. Standard protocol is 2 mg/day SubQ for 30 days, repeated 2–3× per year. Evidence is preclinical and from Russian bioregulator literature; no Western RCTs exist. All RUO.
What Is Livagen?
Livagen is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Ala (KEDA), developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson family of tissue-specific peptides. It was originally isolated from bovine liver extracts and subsequently synthesized as a defined four-amino-acid compound targeting hepatic, lymphocyte, and gastrointestinal/immune cell populations.
Unlike classical receptor-ligand peptides, Livagen acts primarily at the chromatin and epigenetic level — interacting with DNA and histone architecture to de-condense heterochromatin in aged nuclei, restore gene expression profiles toward youthful patterns, and inhibit enzymes that degrade endogenous opioid peptides. It is often compared to Epitalon within the Khavinson peptide family, but is more focused on liver, GI, and immune systems rather than the pineal/circadian axis.
All published research comes from Russian bioregulator literature and preclinical models. There are no FDA-approved indications and no Western-style RCTs. All vendor-supplied Livagen is sold for research use only (RUO).
Mechanism of Action
Chromatin decondensation and gene activation: Livagen induces de-heterochromatinization in lymphocytes and hepatocytes — decondensing heterochromatin that has become pathologically compacted with age. It activates ribosomal genes and pericentromeric structural regions, and influences histone acetylation/methylation to restore transcriptional accessibility in aging liver and immune cells. The proposed outcome is restoration of youthful gene expression profiles in hepatic and lymphocyte populations; exact binding sites remain under investigation.
Hepatic regeneration and circadian biosynthesis: In aged rat hepatocyte cultures, nanomolar concentrations of Livagen significantly increased protein synthesis rates toward levels seen in young cells and repaired circadian biosynthesis rhythms disrupted by aging — effects not observed at supraphysiological concentrations, consistent with a regulatory rather than pharmacological mechanism.
Endogenous opioid system (EOS) support: Livagen inhibits enkephalin-degrading enzymes in human serum (IC₅₀ ≈ 20 µM) more efficiently than established peptidase inhibitors, raising endogenous enkephalin levels. This positions it alongside Epitalon within the Khavinson family's proposed pain, mood, and immune-modulation framework. Antioxidant and anti-inflammatory effects have been hypothesized but are not yet characterized at a mechanistic level.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
Hepatic Support & Liver Regeneration
Livagen improves protein synthesis and restores circadian biosynthesis rhythms in aged hepatocyte cultures. Conceptual applications include chronic liver injury, steatosis, and age-related hepatic decline. Russian bioregulator literature positions it as one of the most compelling Khavinson peptides for hepatoprotection.
GI / Digestive Enzyme Modulation
Oral Livagen in rat studies modulates digestive enzyme activity in an age-dependent manner — reducing activity in young animals and increasing it in old animals — suggesting a normalizing or adaptive effect on GI function across the lifespan.
Immune System & Lymphocyte Chromatin
Livagen decondenses heterochromatin and activates genes in aging lymphocytes. Conceptual applications include immune system rejuvenation, improved responses to infections, and modulation of psychosomatic and stress-linked immune disorders associated with lymphocyte dysfunction in aging.
Endogenous Opioid System & Stress-Related Disorders
By inhibiting enkephalin-degrading enzymes, Livagen may enhance and prolong endogenous opioid tone. Proposed relevance to stress adaptation, psychosomatic disorders, mood regulation, and CNS stress responses — though human therapeutic studies are absent.
Cellular Aging & Epigenetic Research
Livagen is studied as a tool for epigenetic regulation and cellular aging research due to its chromatin-decondensing activity. Its effects on pericentromeric heterochromatin and ribosomal genes make it relevant to aging biology and geroprotective peptide research.
Research Protocols (Educational Only)
Disclaimer — RUO Bioregulator Protocols Only
Livagen protocols are based on Russian bioregulator literature, animal studies, and RUO practice. They are not medical advice and have not been validated in Western-style RCTs. All applications are Research Use Only.
| Goal | Dose | Frequency | Route | Duration |
|---|
| Hepatic Support / Liver Regeneration | 2 mg | Once daily | SubQ | 30 days |
| Immune / Lymphocyte Chromatin Study | 2 mg | Once daily | SubQ | 30 days |
Cycle Pattern & Pharmacokinetics
Standard Khavinson practice: 30-day on-cycle, repeated 2–3 times per year with 3–6 month breaks between cycles. No formal human PK data exist. As a tetrapeptide, plasma half-life is likely short (minutes to a few hours). Functional effects — chromatin decondensation, enzyme inhibition, restored protein synthesis — are cumulative over weeks and may persist beyond the dosing window as epigenetic changes take time to reverse.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Protocol | 1–2 mg | Once daily | SubQ |
| Intensive Course | 2 mg | Once daily | SubQ |
| Maintenance | 1–2 mg | Once daily, for 10{EN}15 days every 3{EN}6 months | SubQ |
Peptide Interactions
Both are chromatin-active Khavinson bioregulators; Livagen is more liver/immune-focused, Epitalon more circadian/pineal. Often conceptualized as a paired aging-research combination.
Organ-specific peptides are conceptually combined to address multiple tissues (liver + heart + thymus) in aging models; evidence is largely Russian and observational.
Livagen inhibits enkephalin-degrading enzymes; combining with opioids or EOS-active compounds could theoretically amplify opioid tone. No formal interaction data exist.
Livagen's suspected antioxidant and cytokine-modulating effects may complement other geroprotective interventions in aging research stacks.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Reported tolerability — no serious adverse events have been reported in published Livagen studies; it appears well tolerated across age groups in Russian research. Rat oral and hepatocyte studies do not report overt toxicity at tested doses.
Chromatin-level action — Livagen operates at the level of gene expression and chromatin architecture; long-term systemic effects of repeated chromatin manipulation are not fully characterized.
EOS enzyme inhibition — effects on the endogenous opioid system may alter stress and pain responsiveness; human therapeutic safety is unknown, particularly with repeated cycles.
Evidence limitations — no Western-style large RCTs; evidence comes from small, mostly Russian studies and cell/animal work. Extrapolation to humans is speculative.
Do Not Use If:
Active opioid dependency or concurrent opioid therapy (EOS enzyme inhibition may unpredictably alter opioid signaling)
Active or suspected malignancy (chromatin remodeling effects and gene activation carry unknown oncological implications)
Outside a supervised, institutional research protocol
Seek Medical Attention If:
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Severe or unusual symptoms following administration
Always consult a licensed physician before and during use
Quality Indicators
Verified
Sequence verification (MS)
Tetrapeptide sequence Lys-Glu-Asp-Ala confirmed by mass spectrometry (MS).
Verified
HPLC purity ≥98%
HPLC purity ≥98%; CoA documenting identity, net content, and batch number.
Verified
Lyophilized powder appearance
White to off-white lyophilized powder; clear, colorless solution upon reconstitution.
Caution
Storage & stability
Lyophilized storage at 2–8 °C or below, protected from light and moisture. Reconstituted solution recommended for use within 30 days refrigerated. Lyophilized powder stable 12–24 months when stored correctly.
CAUTION — NOT RECOMMENDED
Quality concerns
Pre-mixed solutions without documented storage conditions or reconstitution date. Discoloration, cloudiness, or particulate matter indicating degradation or contamination.
Reported Research Timeline
01During the active course (Days 1–30) (reported in cited studies): Livagen (KEDA tetrapeptide) acts at the chromatin and epigenetic level in hepatocytes, lymphocytes, and intestinal immune cells. Early measurable effects include normalization of liver enzyme parameters and improvement in lymphocyte proliferation indices in Russian research data. Subjective effects during this phase are typically subtle — some researchers report improved energy and digestion.
02Weeks 4–8 post-course (reported in cited studies): The epigenetic normalization established during the active course continues to manifest. Liver function markers continue improving. Khavinson research documents enhanced B- and T-cell balance, improved cytokine profiles, and better gut immune function in the weeks following a completed course. Systemic immune resilience improvements are most notable in this phase.
03Months 1–3 (durable effects) (reported in cited studies): Khavinson longitudinal data describe persistent improvements in immune function and hepatic parameters for 3–6 months following a 30-day Livagen course — providing the rationale for the semi-annual repeat cycle. Liver biomarkers (ALT, AST, GGT) normalize toward reference range in subjects with sub-optimal baseline values.
04Long-term (repeat courses) (reported in cited studies): In Khavinson longevity cohort studies, repeated bioregulator use (including Livagen) correlated with reduced biological aging markers, lower incidence of age-related liver disease, and preserved immune function compared to controls. The semi-annual or annual course pattern is the standard geroprotective schedule.
Research Citations
- Effect of the peptide Livagen on chromatin activation in lymphocytes of old and young people
Khavinson VKh et al., 2002, Bull Exp Biol Med
- Peptide Livagen activates ribosomal genes in human lymphocytes
Khavinson VKh, Malinin VV, 2001, Bull Exp Biol Med
- Comparison of effects of Epithalon and Livagen on endogenous opioid system in humans
Khavinson VKh et al., 2004, Bull Exp Biol Med
- Effects of peptide bioregulators on liver protein biosynthesis in old rats
Khavinson VKh, Tarnovskaya SI et al., 2005, Bull Exp Biol Med
"
"
Research Focus
Hepatoprotection, Chromatin Decondensation, Immune Modulation, Endogenous Opioid System, Cellular Aging
Verified Vendors Carrying Livagen
Frequently Asked Questions
What should researchers watch for with Livagen?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Livagen?
During the active course (Days 1–30) (reported in cited studies): Livagen (KEDA tetrapeptide) acts at the chromatin and epigenetic level in hepatocytes, lymphocytes, and intestinal immune cells. Early measurable effects include normalization of liver enzyme parameters and improvement in lymphocyte proliferation indices in Russian research data. Subjective effects during this phase are typically subtle — some researchers report improved energy and digestion.
How is Livagen typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →